Aprinoia Therapeutics (Aprinoia Therapeutics) Accounts Payable : $7.32 Mil (As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Accounts Payable?

Aprinoia Therapeutics's Accounts Payable for the quarter that ended in Jun. 2023 was $7.32 Mil.

Aprinoia Therapeutics's quarterly Accounts Payable increased from Jun. 2022 ($0.00 Mil) to Dec. 2022 ($8.89 Mil) but then declined from Dec. 2022 ($8.89 Mil) to Jun. 2023 ($7.32 Mil).

Aprinoia Therapeutics's annual Accounts Payable increased from . 20 ($0.00 Mil) to Dec. 2021 ($0.43 Mil) and increased from Dec. 2021 ($0.43 Mil) to Dec. 2022 ($8.89 Mil).

Aprinoia Therapeutics Accounts Payable Historical Data

The historical data trend for Aprinoia Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Accounts Payable Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

Accounts Payable

0.43

8.89

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Accounts Payable	0.43	-	8.89	7.32

Aprinoia Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Aprinoia Therapeutics Accounts Payable Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines